202 related articles for article (PubMed ID: 32168417)
21. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
Zimmerman C; Atherton PJ; Pachman D; Seisler D; Wagner-Johnston N; Dakhil S; Lafky JM; Qin R; Grothey A; Loprinzi CL
Support Care Cancer; 2016 Mar; 24(3):1071-8. PubMed ID: 26248652
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
23. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
[TBL] [Abstract][Full Text] [Related]
24. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
26. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.
Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Chang SC; Lan YT; Lin CC; Yen CC; Tzeng CH; Wang WS; Chiang HL; Teng CJ; Teng HW
Support Care Cancer; 2012 Jul; 20(7):1491-7. PubMed ID: 21814779
[TBL] [Abstract][Full Text] [Related]
32. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.
Molassiotis A; Suen LKP; Cheng HL; Mok TSK; Lee SCY; Wang CH; Lee P; Leung H; Chan V; Lau TKH; Yeo W
Integr Cancer Ther; 2019; 18():1534735419836501. PubMed ID: 30905173
[TBL] [Abstract][Full Text] [Related]
35. Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial.
Wei XM; Chen XF; Shu P; Jiang ZW; Wu XY; Zou X; Chen K; Shen B; Hu WW; Lu W; Shen WX; Li L; Wang JY; Zhao FJ; Yin QF; Cheng HB; Gu YH
Medicine (Baltimore); 2020 May; 99(22):e19923. PubMed ID: 32481364
[TBL] [Abstract][Full Text] [Related]
36. Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy: A multicentered, randomized controlled trial.
Ben-Arye E; Hausner D; Samuels N; Gamus D; Lavie O; Tadmor T; Gressel O; Agbarya A; Attias S; David A; Schiff E
Cancer; 2022 Oct; 128(20):3641-3652. PubMed ID: 35960141
[TBL] [Abstract][Full Text] [Related]
37. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
38. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
[No Abstract] [Full Text] [Related]
39. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
40. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
